Three independent discounted-cash-flow-style models value Royalty Pharma plc every trading day. 1 of 3 currently price RPRX above its market price.
| Free Cash Flow model | $47.73 |
| Excess Profit model | $59.06 |
| Residual Earnings model | $12.18 |
| Dividend Discount model | $44.55 |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +8.0% |
| Net debt / EBITDA | 5.3× |
| Gross margin | +100.0% |
| Revenue CAGR | +2.1% |
| Cash conversion | 3.2× |
| Dividend yield | +1.7% |
| Buyback yield | +3.9% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open RPRX in StockKitty